GPR32 Antibody

What is GPR32 and what are its primary functions in cellular signaling?

GPR32 (also known as probable G-protein coupled receptor 32 or resolvin D1 receptor) is a protein encoded by the human GPR32 gene that belongs to the rhodopsin-like subfamily of G-protein coupled receptors. It functions as a receptor for several ligands, including resolvin D1 (RvD1), which it binds with high affinity. This binding leads to rapid and transient activation of numerous intracellular signaling pathways .

GPR32 plays critical roles in inflammation resolution by:

• Enhancing RvD1-stimulated phagocytic and clearance functions in macrophages

• Reducing macrophage migration toward chemoattractant stimuli while increasing phagocytosis of microbial particles

• Preventing calcium increase and ERK1/2 activation used by histamine's H1 receptor to induce goblet cell secretion

• Inhibiting the cyclic adenosine monophosphate signaling pathway under both baseline and forskolin-stimulated conditions

In which human tissues and cell types is GPR32 expressed?

GPR32 expression has been detected in various human cell types, including:

• Neutrophils and lymphocytes

• Macrophages and monocytes

• Small airway epithelial cells (hSAECs)

• Human umbilical vein endothelial cells (HUVEC)

Flow cytometric analysis has confirmed cell-surface expression of GPR32 on human PMNs, monocytes, and differentiated macrophage populations . Interestingly, GPR32 surface expression in human monocytes is up-regulated following exposure to GM-CSF and zymosan, but not by exposure to TNF-α or TGF-β .

How should I select the appropriate GPR32 antibody for my specific application?

When selecting a GPR32 antibody, consider the following methodological approach:

• Determine your application requirements:

  • For Western blotting: Select antibodies validated for WB (e.g., ab79516, ABIN1535742)

  • For immunofluorescence: Choose antibodies validated for ICC/IF (e.g., ab79516, GTX108119)

  • For immunohistochemistry: Use antibodies validated for IHC-P (e.g., ab61429, GTX108119)

  • For flow cytometry: Select FCM-validated antibodies (e.g., GTX108119)

• Consider the epitope location:

  • N-terminal targeting antibodies (e.g., GTX108119 N-term)

  • C-terminal targeting antibodies

  • Internal region antibodies (e.g., AA 151-200 in ABIN1535742)

• Review validation data provided by manufacturers, including images of expected staining patterns in relevant tissues or cell lines .

• Check species reactivity: Most GPR32 antibodies are human-specific, as GPR32 lacks murine homologues .

What are the best practices for validating GPR32 antibody specificity?

To validate GPR32 antibody specificity, implement this methodological approach:

• Overexpression systems:

  • Use GPR32-overexpressing cell lines (e.g., transfected 293T cells) as positive controls

  • Compare staining between mock-transfected and GPR32-overexpressing cells

• Knockdown validation:

  • Perform shRNA or siRNA knockdown of GPR32

  • Compare antibody signals between control and knockdown samples

• Multi-technique confirmation:

  • Confirm protein detection across multiple techniques (e.g., Western blot and immunofluorescence)

  • Verify that molecular weight is consistent with predicted GPR32 size (~40kD theoretical, often observed at ~60kD due to glycosylation)

• Positive controls:

  • Use recommended positive control tissues/cells (e.g., H1299 cells for PA5-28736)

  • Human small intestine tissue neuroendocrine cells have shown positive staining

• Peptide blocking:

  • Pre-incubate the antibody with immunizing peptide to confirm specificity

  • Signal should be significantly reduced in blocked samples

Why might I observe different molecular weights for GPR32 in Western blots?

GPR32 has a theoretical molecular weight of approximately 40kD, but it commonly appears at ~60kD in Western blots due to post-translational modifications, particularly glycosylation . When investigating GPR32 by Western blot:

• Glycosylation effects:

  • The observed band often runs at ~60kD due to enrichment of the glycosylated receptor

  • Some reports note bands at ~30kD and ~130kD, which may represent different glycosylation states or oligomeric forms

• Sample preparation considerations:

  • Using glycoprotein-enriched fractions may enhance detection of the properly processed receptor

  • Deglycosylation treatments can be used to confirm identity of higher MW bands

• Validation approach:

  • Compare GPR32 overexpressing cells with control cells

  • Verify specificity with knockdown experiments

  • Use multiple antibodies targeting different epitopes to confirm band identity

What are the optimal conditions for GPR32 detection by immunofluorescence?

For optimal GPR32 detection by immunofluorescence, follow these methodological guidelines:

• Fixation protocol:

  • Ice-cold methanol fixation for 5 minutes has been successfully used for GPR32 detection in 293T cells

  • Alternative fixations (PFA) may be needed depending on cell type

• Antibody dilutions:

  • Primary antibody: Typically 1:500 dilution (e.g., GPR32 antibody [N1], N-term (GTX108119))

  • Secondary antibody: Fluorophore-conjugated anti-rabbit IgG (e.g., Alexa Fluor 568)

• Staining procedure:

  • Block with appropriate blocking buffer (typically 1-5% BSA or serum)

  • Incubate with primary antibody against GPR32 for 30 minutes (on ice) or overnight at 4°C

  • Wash thoroughly with PBS

  • Incubate with fluorophore-conjugated secondary antibody

  • Counterstain nuclei with DAPI

• Controls:

  • Include mock and GPR32-transfected cells as negative and positive controls

  • Use both primary and secondary antibody-only controls

How can I effectively detect GPR32 in human macrophages for functional studies?

To effectively detect and study GPR32 in human macrophages:

• Macrophage preparation:

  • Differentiate peripheral blood monocytes using appropriate stimuli

  • Flow cytometry confirms GPR32 surface expression in differentiated macrophage populations

• Detection methods:

  • Flow cytometry: Stain with rabbit polyclonal antibody against GPR32 followed by fluorophore-conjugated secondary antibody

  • RT-PCR: Detect GPR32 mRNA expression using specific primers (Forward: 5′-GTGATCGCTCTTGTTCCAGGA-3′, Reverse: 5′-GGACGCAGACAGGATAACCAC-3′)

  • Immunofluorescence: Visualize GPR32 localization in fixed macrophages

• Functional analysis approaches:

  • Phagocytosis assays: RvD1 enhances macrophage phagocytosis of zymosan and apoptotic PMNs in a dose-dependent manner (peaks at 0.1-1.0 nM)

  • GPR32 overexpression: Transiently transfect macrophages with GPR32 expression vectors to enhance RvD1-stimulated phagocytosis

  • GPR32 knockdown: Use shRNA to reduce GPR32 expression and measure decreased RvD1-stimulated phagocytosis

• Receptor regulation studies:

  • Treat with GM-CSF and zymosan to upregulate GPR32 surface expression

  • Monitor changes in inflammation resolution functions

What protocols are most effective for flow cytometric analysis of GPR32?

For effective flow cytometric analysis of GPR32:

• Sample preparation:

  • Gently trypsinize adherent cells to maintain surface receptor integrity

  • For suspension cells or leukocytes, use gentle centrifugation (300-400g)

  • Wash cells thoroughly before antibody staining

• Staining protocol:

  • Stain with rabbit polyclonal antibody against GPR32 for 30 minutes on ice

  • Wash cells thoroughly

  • Stain with fluorophore-conjugated secondary antibody (e.g., Alexa Fluor 568 goat anti-rabbit) for 30 minutes

• Flow cytometer settings:

  • Use forward and side-scatter corrections to exclude doublets

  • Include proper compensation controls if performing multi-color analysis

  • Run samples on an appropriate flow cytometer (e.g., FACSCanto II) and analyze using standard software (e.g., FlowJo)

• Controls and validation:

  • Include isotype controls to determine background staining

  • Use GPR32-transfected vs. mock-transfected cells as positive and negative controls

  • Consider dual staining with ALX/FPR2 to study co-expression patterns

How do GPR32 and ALX/FPR2 receptors cooperate in resolvin D1 signaling pathways?

GPR32 and ALX/FPR2 demonstrate cooperative functions in resolvin D1 signaling through multiple mechanisms:

• Dual receptor engagement:

  • RvD1 binds with high affinity to both GPR32 and ALX/FPR2 receptors

  • The protective effects of RvD1 on endothelial cell integrity and barrier function are blocked by neutralizing antibodies against either DRV1/GPR32 or ALX/FPR2

• Complementary inhibition studies:

  • In small airway epithelial cells (hSAECs), RvD1 inhibits the production of inflammatory mediators IL-6 and IL-8

  • This inhibition is partially blunted by GPR32 neutralizing antibody alone

  • In the presence of both GPR32 antibody and the ALX/FPR2 antagonist Boc-2, the inhibitory effect of RvD1 is fully reversed

• Shared signaling pathways:

  • Both receptors utilize pertussis toxin-sensitive G-protein pathways

  • Neither receptor directly evokes Ca²⁺ mobilization nor changes in cAMP levels upon RvD1 binding

  • Both GPR32 and ALX/FPR2 couple with β-arrestin in a ligand-dependent fashion

• Functional redundancy and specialization:

  • Both receptors enhance phagocytosis and clearance functions

  • Overexpression of either receptor increases RvD1-stimulated phagocytosis

  • Knockdown studies suggest both receptors contribute to the full spectrum of RvD1 actions

What are the challenges in studying GPR32 in animal models and how can they be overcome?

Studying GPR32 in animal models presents several significant challenges:

• Lack of murine GPR32 homologues:

  • GPR32 lacks direct murine homologues, which hampers mechanistic insights and pathophysiological exploration of this receptor in traditional mouse models

  • This limitation is particularly problematic as mice are the most common model for inflammation studies

• Ligand promiscuity:

  • RvD1 signals through both GPR32 and the FPR2/ALX receptor, complicating the isolation of GPR32-specific effects

  • Other resolvins (RvD3, RvD5) also signal through GPR32

• Novel methodological approaches:

  • Development of humanized mouse models: Researchers have created a novel mouse model by introducing the human GPR32 receptor to atherosclerotic apolipoprotein knock-out mice with additional genetic deletion of the FPR2/ALX receptor

  • This approach generates a functional model with GPR32 signaling capabilities in an otherwise GPR32-deficient system

  • Such models allow for the specific study of GPR32-mediated effects in isolation from ALX/FPR2 signaling

• Alternative strategies:

  • Use of selective synthetic agonists that preferentially activate GPR32 over ALX/FPR2

  • Zebrafish models for studying inflammation resolution with possible GPR32 orthologues

  • Human tissue explant studies to maintain native GPR32 expression patterns

How can I distinguish between GPR32 and ALX/FPR2 mediated effects in inflammation resolution studies?

To distinguish between GPR32 and ALX/FPR2 mediated effects in inflammation resolution, implement these methodological approaches:

• Selective receptor antagonism:

  • Use specific neutralizing antibodies against GPR32

  • Apply ALX/FPR2 antagonist Boc-2 to block ALX/FPR2-mediated effects

  • Compare effects of individual receptor blockade versus combined blockade

• Receptor knockdown/knockout strategies:

  • Perform shRNA knockdown of ALX or GPR32 individually or in combination

  • Use CRISPR-Cas9 gene editing for complete receptor knockout

  • Compare phenotypic and functional outcomes between single and double knockdowns

• Overexpression systems:

  • Transiently transfect cells with expression vectors for GPR32 or ALX/FPR2

  • Create stable cell lines expressing only one receptor

  • Measure receptor-specific responses to RvD1 and other ligands

• Ligand specificity exploitation:

  • Use RvD1 stable analogs with preferential binding to one receptor

  • Identify chemotype agonists specific for DRV1/GPR32 through screening libraries

  • Apply computational and structure-based approaches to develop selective ligands

• Downstream signaling analysis:

  • Monitor receptor-specific signaling pathways

  • Use phospho-specific antibodies to track activation of distinct signaling nodes

  • Employ transcriptomic approaches to identify receptor-specific gene signatures

How is GPR32 expression altered in inflammatory diseases and what are the implications for antibody-based detection?

GPR32 expression undergoes significant changes in inflammatory disease states, with important implications for antibody-based detection:

• Expression patterns in disease:

  • GPR32 is dysregulated in human atherosclerotic lesions, indicating disruption of lesional healing processes

  • Transcriptional associations identify resident pro-resolving macrophages as the main host of atherosclerotic GPR32 expression

  • Elevated resolvin D1 levels have been noted in both attack and silent periods of familial Mediterranean fever patients compared to controls

• Antibody detection considerations:

  • Receptor internalization and trafficking may affect epitope accessibility

  • Consider using antibodies against different epitopes (N-terminal, C-terminal, or internal regions)

  • Fixation methods may need optimization for different disease tissues

• Cell-specific expression changes:

  • In macrophages, GPR32 expression promotes polarization toward a pro-resolution phenotype with reduced secretion of proinflammatory cytokines, low chemotaxis, and increased phagocytosis

  • GPR32 signaling in adaptive immune circuits prevents T cell differentiation toward Th1 and Th17 while promoting regulatory T-cell generation

• Methodological implications:

  • Use of multiple antibody detection methods (IHC, IF, flow cytometry) provides complementary information

  • Context-specific validation is essential as expression patterns may vary by disease

  • Consider dual staining with inflammatory markers to correlate GPR32 expression with disease state

What are the current approaches for developing and validating GPR32-targeting therapeutics?

Current approaches for developing and validating GPR32-targeting therapeutics include:

• Identification of chemotype agonists:

  • High-throughput screening of diverse chemical libraries for compounds that stimulate DRV1/GPR32 activity

  • Use of β-Arrestin assays as primary screening tools

  • Counter-screening against other receptors (e.g., BLT1) to ensure specificity

• Validation cascade:

  • Confirmation of hits in dose-response manner

  • Secondary testing in cAMP HTRF signaling assays

  • Cytotoxicity assessment in relevant cell lines (e.g., THP1)

  • Structural clustering analysis to identify diverse chemical scaffolds

• Resolvin mimetics development:

  • Design of stable analogs that maintain GPR32 activation properties

  • Addressing chemical stability issues of native resolvins

  • Development of compounds requiring fewer synthesis steps than native molecules

• Therapeutic target validation:

  • Use of GPR32 antibodies as tool compounds to validate receptor involvement

  • Development of humanized mouse models expressing GPR32

  • Exploration of omega-3 derived lipid mediators as templates for drug development

• Emerging therapeutic applications:

  • Resolution of pulmonary inflammation

  • Suppression of TGFβ-induced epithelial-mesenchymal transition in lung cancer cells

  • Addressing chronic inflammation in atherosclerosis

  • Treatment of inflammatory conditions where resolution mechanisms are impaired

What are the most common technical issues with GPR32 antibodies and how can they be resolved?

For optimal results when working with GPR32 antibodies:

• Always centrifuge antibody solutions briefly prior to opening the vial

• Store concentrated antibody solutions according to manufacturer recommendations

• Include appropriate positive controls (e.g., H1299 cells for certain antibodies)

• Consider the application-specific requirements for sample preparation and detection methods

How should I design experiments to study GPR32 signaling mechanisms?

To effectively study GPR32 signaling mechanisms:

• Receptor activation approaches:

  • Use natural ligands (RvD1, RvD3, RvD5) at physiologically relevant concentrations (0.1-10 nM)

  • Consider stable synthetic analogs or chemotype agonists for consistent activation

  • Compare with ALX/FPR2 selective ligands to distinguish receptor-specific effects

• Signaling pathway analysis:

  • Note that GPR32 activation by RvD1 is pertussis toxin sensitive, indicating Gi/o coupling

  • Monitor changes in actin polymerization and β2 integrin regulation

  • Track specific downstream targets like PKC and GRK2 activation

  • Study effects on ERK1/2 activation pathways

• Functional readouts:

  • Phagocytosis assays using zymosan particles or apoptotic neutrophils

  • Measurement of inflammatory mediator production (e.g., IL-6, IL-8)

  • Cell migration assays to assess chemotactic responses

  • NF-κB activation assays to monitor anti-inflammatory effects

• Advanced analytical approaches:

  • Analysis of miRNAs involved in pro-resolving signaling

  • Monitoring of macrophage polarization toward pro-resolution phenotypes

  • Assessment of T cell differentiation patterns

  • Study of calcium signaling and second messenger responses

When designing these experiments, remember that GPR32 does not directly evoke Ca²⁺ mobilization or changes in cAMP levels upon RvD1 binding , so alternative signaling readouts may be more informative than traditional GPCR assays.